論文・技術情報追加のお知らせ

1. Drug-related retinal detachment pharmacovigilance signals in the real world: evidence from the FDA Adverse Event Reporting System.

FAERSでRD関連薬30種と特徴を同定

対象DB：FAERS

2. Characterizing Fenofibrate-Related Renal and Urinary Adverse Events: A Comprehensive Analysis of FDA Adverse Event Reporting System Database.

FAERSでフェノフィブラート腎尿AEs関連性示唆

対象DB：FAERS

3. Upper Respiratory Tract Infection Associated with Anti-HER2 Antibody Blockade for HER2-Positive Breast Cancer: A Bayesian Disproportionality Analysis Using Data From the FDA Adverse Event Reporting System.

抗HER2でURTIはT-DM1最多・重症傾向確認

対象DB：FAERS

4. Real-world study of adverse events associated with sodium zirconium cyclosilicate based on FDA adverse event reporting system and VigiAccess database.

SZCのFAERS/Vigiで新規安全性シグナル検出

対象DB：FAERS

5. Safety assessment of obinutuzumab: Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025.

FAERS/JADERでオビヌツズマブ新規AE示唆

対象DB：FAERS,JADER

6. Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients.

NSCLCでベバ併用のIP割合、PD-1↑PD-L1↓

対象DB：FAERS

7. Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine.

FAERSでフェンフルラミンAE網羅評価

対象DB：FAERS

8. Age-related differences in hydroxychloroquine-associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System.

FAERSでHCQ有害事象に年齢差・TTO相違確認

対象DB：FAERS

9. Drug-induced Sweet's syndrome: pharmacovigilance insights from FAERS with a cross-database consistency assessment in VigiBase via LASSO and multivariable logistic regression.

FAERSでDISS関連薬特定、発現22日中央値

対象DB：FAERS,VigiBase

10. Sex Differences in Adverse Event Reporting Rates Following COVID-19 Vaccination in South Korea During the Pandemic.

韓国PVでCOVID-19ワクチンAEに性差確認

対象DB：FAERS,KAERS,VAERS

11. Focus on aging, heart failure, regeneration, and cardiovascular medicine.

IACS-NAS特集概観：FAERS等最先端領域紹介

対象DB：FAERS

12. Association between atorvastatin and sarcopenia: a study based on NHANES and FAERS databases.

NHANES＋FAERSでアトルバスタチンとサルコペニア関連示唆

対象DB：FAERS

13. Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database.

FAERSでICI膵炎シグナル、薬剤別リスク差とTTO判明

対象DB：FAERS

14. Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System.

FAERSでシクロベンザプリンの既知・新規AE特定

対象DB：FAERS

15. Real-world Hepatobiliary Toxicity After Bispecific T-Cell Engager Therapy: A 10-Year Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System and the World Health Organization's Global Individual Case Safety Report Database.

BiTE肝胆毒性解析、CD19型で早期重篤傾向

対象DB：FAERS,VigiBase

16. Exploration of the potential association between new oral anticoagulants and anxiety symptoms adverse events: Evidence from a real-world analysis.

アピキサバンで不安症状シグナル、長期注意

対象DB：FAERS

17. Comprehensive analysis of metformin-associated lactic acidosis: Insights from the FDA Adverse Event Reporting System (FAERS).

FAERSでMALAリスク因子・発現時期特定

対象DB：FAERS

18. What does data on adverse reactions reveal about benzodiazepines and suicide-related risk?: A disproportionality analysis using FDA FAERS pharmacovigilance data.

FAERSでBZD自傷リスク薬差、性年齢差異判明

対象DB：FAERS

19. A retrospective pharmacovigilance study of ocrelizumab in multiple sclerosis: Analysis of the FDA Adverse Event Reporting System (FAERS) database.

FAERSでオクリ服用AE既知＋新規シグナル検出

対象DB：FAERS

20. Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system.

FAERSでTMA関連薬30種シグナル、抗腫瘍薬優勢

対象DB：FAERS

21. Temporal trends in treatment-related cardiopulmonary disease-specific mortality in NSCLC based on pathological subtypes: a retrospective population-based cohort study.

NSCLCで心肺死増、特にLADC・免疫治療後

対象DB：FAERS

22. Real-World Safety of Anti-EGFR Antibodies: 20-Year Pharmacovigilance of Cetuximab and Panitumumab.

FAERSでセツキシマブ/パニ多数AE差異判明

対象DB：FAERS

23. Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout.

FAERSとMRで高血圧→痛風因果、薬剤因果否定

対象DB：FAERS

24. Drug reaction with eosinophilia and systemic symptoms syndrome in association with novel antineoplastic pharmacotherapy: Characterizing reported clinical patterns and outcomes utilizing the Food and Drug Administration Adverse Event Reporting System database.

FAERSで新規抗がん薬関連DRESSの臨床像解析

対象DB：FAERS

25. Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA Database.

FAERSでSCAR大規模解析、薬剤多様・潜時差あり

対象DB：FAERS

26. Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database.

T-DXdで早期発症の肺障害多く重篤例あり

対象DB：JADER

27. Pharmacovigilance and toxicological risks associated with apitherapeutic products: a systematic overview.

蜂産品は有益でも有害事象あり、警戒要

対象DB：EudraVigilance

28. Human papillomavirus-related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase(R).

MS高効能薬でHPV関連事象報告増加傾向

対象DB：VigiBase

29. Sex and Age Differences in Suspected Bleeding Reporting With Acetyl Salicylic Acid: A Descriptive Study in the Global Pharmacovigilance Database, Vigibase.

ASA関連出血は男性・高齢で報告高率

対象DB：VigiBase

30. Impact of COVID-19 state of emergency declarations on percutaneous coronary intervention volumes in Japan: a SARIMAX analysis of nationwide DPC database (2018-2021).

緊急事態でPCI減少、SARIMAXで定量化

対象DB：DPC

31. Hospital volume impact on multiple sclerosis outcomes: a retrospective cohort study using a nationwide administrative database in Japan.

高症例病院で再入院遅延、在院日数差なし

対象DB：DPC

32. Mortality after broad- versus narrow-spectrum antibiotic treatment for patients with nursing and healthcare-associated pneumonia: A nationwide retrospective cohort study.

NHCAPで広域薬は短期死亡率に非優位

対象DB：DPC

33. Prognostic comparison of acute exacerbations across idiopathic interstitial pneumonia subtypes: A nationwide observational study.

AE-IIPでIPF/NSIP/AIPはCOPより高死亡率

対象DB：DPC

34. GLIM Criteria-defined malnutrition and short-term mortality in acute care hospitals: A nationwide claims-based historical cohort study.

GLIM栄養不良・未評価で死亡率上昇示唆

対象DB：DPC

35. Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study.

EGD前GLP-1RA中止不要示唆も新規・重症例注意

対象DB：JMDC

36. Postpartum diabetes screening for women with gestational diabetes in Japan: an administrative database study.

産後OGTT受検低調、同施設管理で向上

対象DB：JMDC

37. Trends and Seasonal Patterns of Intussusception in Japan: A Retrospective Database Study of Weather and Infectious Disease Associations.

夏季発生増、件数減少と気温湿度・咽頭結膜熱関連

対象DB：NDB

38. Trends of shoulder arthroplasty and rotator cuff repair in Japan: national database analysis.

肩関節置換増加、RCRも増え性差・高齢化傾向

対象DB：NDB

39. Regional Differences in Characteristics, Service Utilization, and Outcome of Patients Receiving Physician-Led Home Visit Care in Japan: A Nationwide Study.

地域差大きく資源と入院・在宅死関連

対象DB：NDB

40. Real-world use of HIF-PH inhibitors and ESAs in non-dialysis-dependent CKD with anemia: insights from a Japanese database study.

日本でHIF-PH開始増、ESAより貧血改善傾向

対象DB：MDV

41. Socioeconomic inequality and modifiable cardiovascular risk factor clusters among consulters with and without osteoarthritis in England.

OA患者で社会的格差と心血管危険因子集積増加

対象DB：CPRD

42. Risk of stroke associated with risperidone in dementia with and without comorbid cardiovascular disease: population-based matched cohort study.

リスペリドンで認知症患者の脳卒中リスク増加

対象DB：CPRD

43. Prostate specific antigen retesting intervals and trends in England: population based cohort study.

PSA再検査は頻回で地域差、過検査懸念

対象DB：CPRD

44. The cost of migraine to the NHS in England: a retrospective cohort study using electronic health record data from Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES).

片頭痛は医療費が高く二次医療が主因

対象DB：CPRD

45. Incidence of suicide within two years of a first diagnosis of depression, anxiety, or mixed anxiety and depression: an exploratory cohort study in primary care using the Clinical Practice Research Datalink.

初診2年内の自殺率は男性で高く高齢男性で最大

対象DB：CPRD